VIDA FLaSH Acquisitions in a letter to the SEC said it would withdraw a planned offering of 15 million units, which was downsized in May from the 17.5 million units initially registered with the regulator in February 2021.
The SPAC had planned to target the healthcare sector in the United States.
VIDA is led by CEO and Director Dr. Frank Litvack, an interventional cardiologist and former co-director of the Cardiovascular Intervention Center at Cedars Sinai in Los Angeles and a Professor of Medicine at UCLA.
The SPAC had intended to list on the Nasdaq. Read more.
